Advances in biotechnology have ensured a world of opportunities for biosimilars to enter the market and serve the needs of patients in a cost-effective manner. However, Pharmacovigilance and risk ... management for…
Almost one decade back the first biosimilar was launched in Europe. Now they have 15 biosimilars and all are well accepted since high price branded biologics were tough to reach ... many patients. Recently biosimilars…
patents for several of these biologics drugs, manufacturers around the world are developing biosimilars to these biologics. Biosimilars present a significant opportunity for the healthcare systems to mitigate challenges…
bring a breakthrough in terms of health cost. These imitated products are termed as biosimilar products. Although the history of biosimilars started at European Union (EU) in 2006 with single ... currently it has been…
With the big success of biologicals and the experience in generics, the biosimilar development was born. In Europe, the first biosimilars were already approved in the 2006 and since then ... especially in Europe…
development pathway of a biosimilar is unlike that of a novel biotherapeutic. Many regulatory authorities reference a “step-by-step” approach to establishing biosimilarity. In the early stages there ... lytics. This…
owing to the complexity and nature of the molecule, development and commercialisation of a Biosimilar is two fold challenging. The Biosimilar is not only required to meet safety and efficacy ... developed and validated…
biosimilar product is a biological product that is approved based on showing that it is highly similar to the reference product, with no clinically meaningful differences in terms of safety ... efficacy and quality from…
regulatory guidance, one should discuss the relevance of the current clinical development model for biosimilars and raise the following long-term questions: is it the end of clinical trials ... biosimilar development,”…
biosimilar product is a biological product that is approved based on showing that it is highly similar to an already approved biological product, known as the reference product. The biosimilar ... meaningful differences…
Biosimilars were touted as a payer’s tool to gain savings in specialty markets, but a recent survey by Avalere of the top 25 payers in the U.S. (about ... million covered lives) using publicly available coverage…
Nine years after the passage of the biologics and biosimilars price competition and innovation act, 14 biosimilar agents have been approved by the US Food and Drug Administration but only ... biosimilars have reached…
biosimilars industry in the United States is still a nascent one. In 2015, FDA approved the rst biosimilar biological product and several other approvals have followed, with more applications ... other biosimilar…
Biosimilars uptake in Asia has been historically low. Recent evolutions in regional regulations are preparing the market for a step change. Countries like Japan and South Korea have developed their ... regulatory…
Patient acceptance of biosimilars over innovator biologics continues to be marginal in many parts of the world. Biologics are complex drugs which are created using recombinant DNA technology. Developing identical…
Biosimilar Era has arrived in the US! The past few months have seen the first ever FDA approval of a biologic deemed biosimilar to a previously approved biologic, the first ... cases of the Federal Circuit addressing…
ready for the biosimilars boom? to most, biosimilars are a no-brainer. But as with anything new, there are early adopters and sceptics. The NIHR CRN is an independent, government ... insight. The NIHR CRN can report…
that include such biological factors as cytokines, hormones, clotting factors, monoclonal antibodies, vaccines, etc. Biosimilars are attempted copies of existing biological medicinal products or protein drugs. They are…
BPCI Act) in US established a regulatory pathway for the approval and marketing of biosimilars in US. FDA subsequently published a number of general guidance documents between ... regulatory process and clarifies the…
Biosimilar Act, passed in 2007 under 351(k), states that a biosimilar product should be ?highly similar? to prior approved reference product (RLD) and will have ?no clinically meaningful differences ... their safety or…
years $71 billion in worldwide biopharmaceutical revenue may be affected by the launch of biosimilar products. Several biosimilar launchs already have taken place in multiple countries, and observations from uptake…
global drug regulators are the scientific and technical factors related to a determination of biosimilarity or interchangeability. Biosimilar drugs are demanding and expensive to get approved, complicated and…
therapeutic proteins in the treatment of their cancer or autoimmune disorders. The development of biosimilars is a complex and expensive undertaking, the more as what is called “reference compound ... manufacturing…
Biosimilars are increasingly being developed by many companies and used as therapeutics for various diseases worldwide. There is a lot of scope to improve in biosimilar story. Biosimilar products ... Australia following…
While the US biosimilar market has lagged behind Europe for almost a decade due to delays concerning the release of specific guidelines by the FDA, the market is poised ... Remicade, and Humira will lose patent…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.